CAR-T Cell Manufacturing — Serum, Media & Single-Use Bag Selection Guide
Chimeric antigen receptor T cell (CAR-T) therapy is one of the fastest-growing areas of biopharmaceutical manufacturing. Five CAR-T therapies have received FDA approval since 2017, and the pipeline of clinical programmes entering Phase I/II continues to expand globally. Every stage of CAR-T manufacturing — from T cell isolation through activation, transduction, expansion, and formulation — requires specific biological materials whose grade, specification, and regulatory documentation directly determine process success and regulatory compliance.
This guide covers the complete CAR-T manufacturing workflow and the specific SeamlessBio products for each stage — from early R&D through GMP Phase I/II production.
CAR-T Manufacturing — Phase Overview & Product Requirements
| Phase | Process Step | Recommended Product | Key Specification |
|---|---|---|---|
| R&D Process Development | T cell isolation, activation screening, vector optimisation | FBS Ultra Low IgG <5 µg/mL | Low IgG prevents FcR competition in T cell activation assays; cost-effective for screening |
| R&D → GMP T Cell Activation | CD3/CD28 stimulation, IL-2 supplementation, pre-expansion | Human Serum AB Male OTC or Human Serum AB HI | OTC: max growth factors (PDGF, EGF, TGF-β) from platelet degranulation. HI: when complement must be inactivated during activation |
| GMP Ex Vivo T Cell Expansion | Large-scale CAR-T expansion in static bags or bioreactors | Human Serum AB Male OTC | Goldstandard — AB type (no anti-A/B lysis), male-only donors (no hormonal variability), off-the-clot (max native growth factors). EMA/410/01 preferred ancillary material. |
| GMP Bioreactor Expansion | Rocking bag bioreactor scale-up (0.5–50 L) | Rocker Bag 0.5–200 L | Compatible with Corning and HyPerforma platforms. ISO 13485. Gamma sterilised. Custom ports available. |
| GMP Media Preparation | Serum-free medium preparation, buffer formulation | rHSA Premium Grade + 2D Bioprocessing Bags | rHSA as albumin source in defined xeno-free media. 2D bags for media storage and transfer. |
| GMP Harvest & Formulation | Cell harvest, wash, formulation in cryopreservation medium | 2D Single-Use Bags + HSA | 2D bags for closed transfer and storage. HSA as protein stabiliser in formulation buffer. |
| QC Release Testing | Cytotoxicity, ELISpot, ADCC assay development | FBS Very Low Endotoxin ≤1 EU/mL + Human Serum AB HI | VLE FBS for ELISpot background reduction. Human Serum AB HI for PBMC-based release assays. |
Why Human Serum AB Male OTC is the CAR-T Gold Standard
The selection of Human Serum Type AB, male-only donors, off-the-clot is not arbitrary — each specification directly addresses a biological or regulatory requirement in CAR-T manufacturing:
| Specification | Why It Matters in CAR-T |
|---|---|
| Type AB | Serum Type AB contains no anti-A or anti-B antibodies. In CAR-T expansion cultures where donor T cells from any blood group are expanded, non-AB serum can cause anti-A/B-mediated agglutination and lysis of residual red blood cells — elevating background cell death and compromising expansion yield. |
| Male donors only | Female donor serum contains hormonal variability (oestrogen, progesterone) that correlates with menstrual cycle. These hormones affect T cell activation thresholds, cytokine production, and expansion kinetics — introducing lot-to-lot variability. Male-only pools eliminate hormonal interference and reduce phenotypic variability between lots. |
| Off-the-Clot (OTC) | OTC serum is collected by coagulation without any centrifugation-based platelet removal. This preserves maximum concentrations of platelet-derived growth factors — PDGF, TGF-β, EGF, IGF-1 — that are released during clot formation. These factors are critical for T cell activation signal amplification and ex vivo expansion yield. Serum from centrifuged or platelet-poor preparations has significantly lower growth factor content. |
| Human (not bovine) | EMA/410/01 explicitly discourages FBS in ATMP manufacturing. FBS introduces bovine xenogenic antigens that can sensitise expanded T cells and generate anti-bovine immune responses in the patient following infusion. Human serum eliminates xenogenic antigen exposure and provides a physiologically matched matrix for human T cell expansion. |
Human Serum Portfolio for CAR-T — All Grades Explained
| Product | CAR-T Application | Phase | Key Advantage |
|---|---|---|---|
| Human Serum AB Male OTC | Ex vivo T cell expansion — primary expansion medium supplement | R&D → GMP Phase I/II | Max growth factors from platelet degranulation. No anti-A/B. No hormonal variability. EMA/410/01 preferred. |
| Human Serum AB Heat Inactivated | T cell activation phase when complement must be inactivated. ELISpot and PBMC-based QC release assays. | R&D, QC | 56°C/30 min — complement destroyed. For protocols where complement-mediated activation of T cells during stimulation is undesirable. |
| Human Serum AB Male (non-OTC) | Early R&D screening, process development before GMP commitment | R&D | Lower cost than OTC for high-volume R&D screening. Same AB type and male donor specification. |
| Human Serum Mixed HI | General T cell maintenance medium when AB type not required | R&D | Complement-inactivated. For research protocols not requiring AB blood group specification. |
| rHSA Premium Grade | Protein supplement in defined xeno-free serum-free media. Formulation buffer for harvest and cryopreservation. | GMP Phase I/II, xeno-free protocols | Recombinant — no blood donor variability. Defined composition. For xeno-free manufacturing where no human-derived serum can be used. |
| HSA (Human Serum Albumin) | Formulation buffer stabiliser. Cryopreservation medium protein source. | GMP formulation | Native HSA as stabilising protein in final formulation buffer for CAR-T cell product. |
FBS in CAR-T — When It Is Still Used and Which Grade
| CAR-T Application | FBS Grade | Why This Grade |
|---|---|---|
| Early process development — T cell activation screening | FBS Ultra Low IgG <5 µg/mL | Bovine IgG in standard FBS occupies FcγR on T cells and APCs — interfering with CD3/CD28 stimulation signals. Ultra Low IgG eliminates this background in activation screening assays. |
| ADCC assay development for CAR-T potency | FBS Ultra Low IgG <5 µg/mL | Bovine IgG competes with therapeutic CAR construct for FcγR binding in ADCC assays — must be eliminated. |
| ELISpot / PBMC-based potency assays | FBS Very Low Endotoxin ≤1 EU/mL | Endotoxin activates monocytes in PBMC preparations — generating non-specific IFN-γ background that masks CAR-T-specific cytotoxic response. |
| Non-clinical murine CAR-T studies | FBS Low Endotoxin ≤5 EU/mL | Standard grade for syngeneic mouse tumour models and in vitro murine T cell culture where human serum is not required. |
Single-Use Bags for CAR-T Manufacturing
Single-use bioprocessing bags eliminate cleaning validation, reduce cross-contamination risk between patient batches, and support the closed and sterile manufacturing environment required for CAR-T GMP production.
| Product | Volume Range | CAR-T Application | Key Specification |
|---|---|---|---|
| Rocker Bag | 0.5–200 L | Ex vivo T cell expansion on rocking wave bioreactor platforms (Corning, HyPerforma compatible) | EVA/LDPE or USP Class VI multilayer PE. Gamma sterilised ≥25 kGy. ISO 13485. Custom port configurations available. |
| 2D Bioprocessing Bags | 150 mL–50 L | Media preparation, buffer storage, cell transfer between process steps, cryopreservation medium storage | USP Class VI. Gamma sterilised. Drop-in for Sartorius Flexboy®. ISO 13485 Germany. |
| 3D Bioprocessing Bags | 50–1,000 L | Large-volume media preparation, buffer preparation for clinical-scale CAR-T manufacturing facilities | MPX tubing connectors. GMP documentation package. ISO 13485. Gamma sterilised. |
Regulatory Documentation — What You Need for Phase I/II CAR-T
| Document | SeamlessBio Availability | Regulatory Requirement |
|---|---|---|
| Certificate of Analysis (CoA) | ✅ Included with every lot | Mandatory — all ancillary materials |
| Certificate of Origin (CoO) | ✅ Included with every lot | Mandatory — traceability of human-derived materials |
| TSE/BSE Statement | ✅ Included | EMA Eudralex Vol. 4 Part IV |
| Ph. Eur. 5.2.12 Declaration | ✅ On request | Ph. Eur. 5.2.12 — human-derived ancillary materials for ATMP |
| Eudralex Vol. 4 Part IV Compliance | ✅ On request | GMP Part IV — ATMPs including CAR-T |
| Viral Testing Panel | ✅ Per lot — HIV, HBV, HCV, CMV, EBV, Parvovirus B19 | ICH Q5A — viral safety of human-derived materials |
| Batch reservation | ✅ Up to 6 weeks — no cost during reservation phase | Process validation requirement — same lot throughout Phase I/II |
| Irradiation certificate (Rocker Bag / 2D Bag) | ✅ Included — validated per ISO 11137 | Single-use bag sterility documentation |
Serum Transition: FBS → Human Serum in CAR-T Protocols
For laboratories transitioning from FBS-based to human serum-based CAR-T expansion protocols — a validated stepwise approach minimises expansion disruption:
| Week | Medium Composition | Monitoring Parameters |
|---|---|---|
| Week 1 | 50% FBS Ultra Low IgG + 50% Human Serum AB Male OTC (same total serum %) | Viability, fold expansion, activation marker expression (CD25, CD69) |
| Week 2 | 25% FBS Ultra Low IgG + 75% Human Serum AB Male OTC | Growth curve comparison, cytokine profile (IFN-γ, IL-2, TNF-α) |
| Week 3+ | 100% Human Serum AB Male OTC at 5–10% | Confirm ≥95% viability, stable fold-expansion, phenotype maintenance (CD4/CD8 ratio, memory markers) |
| Optional | Stepwise serum reduction → defined xeno-free: 5% → 2% → 0% with rHSA supplementation | Full serum-free protocol validation for GMP Phase I/II submission |
Frequently Asked Questions
Why is Human Serum AB Male OTC preferred over AB Female or mixed-gender pools?
Male-only donor serum eliminates hormonal variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production in a cycle-dependent manner. Mixed-gender or female pools introduce hormonal lot-to-lot variability that can manifest as inconsistent CAR-T expansion yields between manufacturing runs — a critical quality issue in GMP production where process consistency is a regulatory requirement.
Can I use FBS for Phase I/II CAR-T trials?
EMA/410/01 discourages FBS in clinical ATMP manufacturing and requires justification if animal-derived ancillary materials are used. For Phase I/II IND/CTA submissions to EMA or FDA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional safety testing documentation. SeamlessBio recommends transitioning to Human Serum AB Male OTC for all GMP-phase CAR-T manufacturing.
What batch size of Human Serum AB Male OTC is typical for Phase I CAR-T?
For Phase I autologous CAR-T manufacturing — typically 3–10 patient batches — a lot reservation of 500 mL to 2 L is usually sufficient for the full Phase I programme when using 5–10% serum in expansion medium. SeamlessBio offers batch reservation for up to 6 weeks at no cost during the validation phase, allowing you to test the lot before committing.
Which single-use bag size for CAR-T rocking bioreactor expansion?
For autologous CAR-T Phase I manufacturing, 0.5–5 L rocker bags are typical — matching the cell numbers from a single patient apheresis. For allogeneic or iPSC-derived CAR-T at larger scale, 10–50 L bags are standard. SeamlessBio rocker bags are available in all sizes from 0.5 L to 200 L and are compatible with Corning and Thermo Fisher HyPerforma rocking platforms.
Is rHSA or native HSA preferred in xeno-free CAR-T formulation?
For fully xeno-free protocols, rHSA Premium Grade is preferred — it has no donor-to-donor variability and no risk of blood-borne pathogen transmission. For GMP formulation buffers where some batch variability is acceptable, native HSA with full viral testing documentation is a cost-effective alternative. Both are available from SeamlessBio with full GMP documentation.
Related Applications
| Application | Link |
|---|---|
| Cytotoxicity Assays (ADCC, CDC, ELISpot) | Cytotoxicity Assay Serum Guide → |
| FBS vs Human Serum — when to switch | FBS vs Human Serum Guide → |
| Single-Use Bioprocessing overview | Single-Use Bioprocessing → |
| Human Serum portfolio | Human Sera & Plasma overview → |
Technical enquiries, batch reservation, Ph. Eur. 5.2.12 documentation: info@seamlessbio.de | +49 851 37932226